Mablytics – Holding a key to precision-guided immunotherapy
We’re developing fully human monoclonal antibodies directed at a novel target that presents a breakthrough for the more effective, safer delivery of therapy in certain oncological diseases. See how our innovation is taking immunotherapy in a new direction.
OUR DRIVING
INSPIRATION
Innovation is our life-blood—it fuels our drive that ultimately helps physicians to treat with conviction, with clarity, and with care. Our deeper understanding of a cell-surface protein has elevated our ability to engineer better immunotherapies and provide hope for the future—paving the way to improve the lives of people diagnosed with difficult-to-treat cancers around the world.
OUR DRIVING
INSPIRATION
Innovation is our life-blood —it fuels our drive that ultimately helps physicians to treat with conviction, with clarity, and with care. Our deeper understanding of a cell-surface protein has elevated our ability to engineer better immunotherapies and provide hope for the future—paving the way to improve the lives of people diagnosed with difficult-to-treat cancers around the world.
OUR SCIENCE
Mablytics is a preclinical stage biotechnology company developing immunotherapies that are precisely delivered by means of a novel target.
Recent studies have demonstrated highly restricted expression of the novel target in normal tissues but overexpression in certain cancers. Immunotherapies directed at this target have the potential for highly effective treatment with low toxicity.
With enhanced knowledge about the unique expression of this target, Mablytics is opening the door to a more potent and yet safer immunotherapy. A new generation of patients will benefit by having targeted therapies selectively delivered to tumor cells across multiple cancer types, all with minimal effects on noncancerous cells.
OUR SCIENCE
Mablytics is a preclinical stage biotechnology company developing immunotherapies that are precisely delivered by means of a novel target.
Recent studies have demonstrated highly restricted expression of the novel target in normal tissues but overexpression in certain cancers. Immunotherapies directed at this target have the potential for highly effective treatment with low toxicity.
With enhanced knowledge about the unique expression of this target, Mablytics is opening the door to a more potent and yet safer immunotherapy. A new generation of patients will benefit by having targeted therapies selectively delivered to tumor cells across multiple cancer types, all with minimal effects on noncancerous cells.
OUR TEAM
The Mablytics Leadership Team—a cohort of seasoned experts
Scientific Advisory Board
Amir T. Fathi, MD
Director of Leukemia Program,
Massachusetts General Hospital
Associate Professor, Medicine,
Harvard Medical School
Anthony Sinsky Sc.D.
Professor of Microbiology
Faculty Director of MIT Center for Biomedical Innovation
Massachusetts Institute of Technology
Chris Kaiser, Ph.D
Amgen Professor of Biology
Massachusetts Institute of Technology
Kendra Sweet, MD, MS
Associate Member, Clinical Research Director
H. Lee Moffitt Cancer Center
Farhad Ravandi, MD
Professor of Medicine
Chief Section of AML
University of Texas—M.D. Anderson Cancer Center
OUR TEAM
The Mablytics Leadership Team—a cohort of seasoned experts
Scientific Advisory Board
Amir T. Fathi, MD
Director of Leukemia Program,
Massachusetts General Hospital
Associate Professor, Medicine,
Harvard Medical School
Anthony Sinsky Sc.D.
Professor of Microbiology
Faculty Director of MIT Center for Biomedical Innovation
Massachusetts Institute of Technology
Chris Kaiser, Ph.D
Amgen Professor of Biology
Massachusetts Institute of Technology
Kendra Sweet, MD, MS
Associate Member, Clinical Research Director
H. Lee Moffitt Cancer Center
Farhad Ravandi, MD
Professor of Medicine
Chief Section of AML
University of Texas – M.D. Anderson Cancer Center
OFFICES
San Diego
3210 Merryfield Row
San Diego, CA 92121
New York
400 Madison Avenue, Suite 11D
New York, NY 10017
917-669-0352
For more information, contact us at
[email protected]
OFFICES
San Diego
3210 Merryfield Row
San Diego, CA 92121
New York
400 Madison Avenue, Suite 11D
New York, NY 10017
917-669-0352
For more information, contact us at [email protected]